AMC1 MED.B.090 Oncology

• ED Decision 2019/002/R found in: Aircrew (1178/2011) Part-FCL Part-MED Part-CC Part-ARA Part-ORA Part-DTO (Dec 2024)

AMC1 MED.B.090 Oncology ED Decision 2019/002/R (a)Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that: (1)     after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2)     time appropriate to the type of tumour and primary treatment has elapsed; (3)     the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low; (4)     there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy; (5)     satisfactory oncology follow-up reports are provided to the medical assessor of the licensing authority. (b)     An OML should be applied as appropriate. (c)      Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (d)     Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up. AMC1 MED.B.090 Oncology ED Decision 2019/002/R (a)Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that: (1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour and primary treatment has elapsed; (3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy; (5) satisfactory oncology follow-up reports are provided to the medical assessor of the licensing authority. (b) An OML should be applied as appropriate. (c) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (d) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up. ##### AMC1 MED.B.090 Oncology *ED Decision 2019/002/R* (a)Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that: (1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour and primary treatment has elapsed; (3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy; (5) satisfactory oncology follow-up reports are provided to the medical assessor of the licensing authority. (b) An OML should be applied as appropriate. (c) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit. (d) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up.